Browsing Tag
cardiometabolic innovation
1 post
Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition
Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more.